112 / 374
Patología respiratoria y cutánea inducida por eosinófilos
112
mepolizumab in eosinophilic asthma.
N Engl J Med 2014;371:1189–97.
40. Ortega HG, Liu MC, Pavord ID, Brus-
selle GG, FitzGerald JM, Chetta A, et
al. MepolizumabTreatment in Patients
with Severe Eosinophilic Asthma. N
Engl J Med 2014;371:1198–207.
41. Haldar P, Brightling CE, Hargadon B,
Gupta S, Monteiro W, Sousa A, et al.
Mepolizumab and exacerbations of re-
fractory eosinophilic asthma. N Engl J
Med 2009;360:973–84.
42. Ortega H, Chupp G, Bardin P, Bourdin
A, Garcia G, Hartley B, et al.The role of
mepolizumab in atopic and nonatopic
severe asthma with persistent eosino-
philia. Eur Respir J 2014;44:239–41.
43. Castro M, Wenzel SE, Bleecker ER, Pi-
zzichini E, Kuna P, Busse WW, et al.
Benralizumab, an anti-interleukin 5 re-
ceptor
α
monoclonal antibody, versus
placebo for uncontrolled eosinophilic
asthma: a phase 2b randomised do-
se-ranging study. Lancet Respir Med
2014;2:879–90.
44. Lim H, Nair P. Efficacy and safety of
reslizumab in patients with moderate
to severe eosinophilic asthma. Expert
Rev Respir Med 2015;1–8.
45. Castro M, Zangrilli J,Wechsler ME, Ba-
teman ED, Brusselle GG, Bardin P, et
al. Reslizumab for inadequately con-
trolled asthma with elevated blood
eosinophil counts: results from two
multicentre, parallel, double-blind,
randomised, placebo-controlled, pha-
se 3 trials. Lancet Respir Med 2015;doi:
10.1016/S2213–600(15)00042–9.
46. Noonan M, Korenblat P, Mosesova S,
Scheerens H, Arron JR, Zheng Y, et al.
Dose-ranging study of lebrikizumab in
asthmatic patients not receiving inha-
led steroids. J Allergy Clin Immunol
2013;132:567–74.e12.
47. Corren J, Lemanske RF, Hanania
NA, Korenblat PE, Parsey M V, Arron
JR, et al. Lebrikizumab treatment in
31. Takeda K, Shiraishi Y, Ashino S, Han J,
JiaY,Wang M, et al. Eosinophils contri-
bute to the resolution of lung-allergic
responses following repeated aller-
gen challenge. J Allergy Clin Immunol
2015;135:451–60.e5.
32. Cheung DS, Grayson MH. A survi-
vor: The eosinophil as a regulator
in asthma. J Allergy Clin Immunol
2015;135:461–2.
33. Noda S, Krueger JG, Guttman-Yassky
E. The translational revolution and use
of biologics in patients with inflamma-
tory skin diseases. J Allergy Clin Im-
munol 2015;135:324–36.
34. Leung DYM, Guttman-Yassky E. De-
ciphering the complexities of ato-
pic dermatitis: shifting paradigms in
treatment approaches. J Allergy Clin
Immunol 2014;134:769–79.
35. Suárez-Fariñas M, Dhingra N, Gittler
J, Shemer A, Cardinale I, de Guzman
Strong C, et al. Intrinsic atopic derma-
titis shows similarTH2 and higherTH17
immune activation compared with ex-
trinsic atopic dermatitis. J Allergy Clin
Immunol 2013;132:361–70.
36. Quirce S, Bobolea I, Domínguez-Orte-
ga J, Barranco P. Future biologic the-
rapies in asthma. Arch Bronconeumol
2014;50:355–61.
37. Flood-Page P, Swenson C, Faiferman I,
Matthews J, Williams M, Brannick L, et
al. A study to evaluate safety and effica-
cy of mepolizumab in patients with mo-
derate persistent asthma. Am J Respir
Crit Care Med 2007;176:1062–71.
38. Pavord ID, Korn S, Howarth P, Bleecker
ER, Buhl R, Keene ON, et al. Mepoli-
zumab for severe eosinophilic asth-
ma (DREAM): A multicentre, double-
blind, placebo-controlled trial. Lancet
2012;380:651–9.
39. Bel EH,Wenzel SE,Thompson PJ, Praz-
ma CM, Keene ON, Yancey SW, et al.
Oral glucocorticoid-sparing effect of